| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802721902018 | 272190201 | OXALIPLATIN/HOSPIRA C/S.SOL.IN 5MG/ML BTx1 VIAL x10 ML | 26.43 | 27.72 | 38.20 |
| 05/2018 | 2802721902025 | 272190202 | OXALIPLATIN/HOSPIRA C/S.SOL.IN 5MG/ML BTx1 VIAL x20 ML | 52.86 | 55.45 | 70.53 |
Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
There have been five cases of oxaliplatin overdose reported. One patient received two 130 mg/m2 doses of oxaliplatin (cumulative dose of 260 mg/m<sup>2</sup>) within a 24-hour period. The patient experienced Grade 4 thrombocytopenia (<25,000/mm<sup>3</sup>) without any bleeding, which resolved. Two other patients were mistakenly administered oxaliplatin instead of carboplatin. One patient received a total oxaliplatin dose of 500 mg and the other received 650 mg. The first patient experienced dyspnea, wheezing, paresthesia, profuse vomiting and chest pain on the day of administration. She developed respiratory failure and severe bradycardia, and subsequently did not respond to resuscitation efforts. The other patient also experienced dyspnea, wheezing, paresthesia, and vomiting.
Bioavailability is complete following intravenous administration.
Approximately 10 - 25 minutes
The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.
* 440 L